This study examines patient perceptions regarding the tolerability of two classes of glaucoma medication: bimatoprost and latanoprost.
Patients enrolled in this study completed a validated survey instrument (COMTOL) examining tolerability of topically applied ophthalmic medications that they are already taking in their regular course of care for glaucoma. The purpose of the study is to determine whether side effects and symptoms of the drugs already being taken cause problems with activities of daily living.
Study Type
OBSERVATIONAL
Enrollment
211
Harvard Eye Associates
Laguna Hills, California, United States
Tolerability of Medications as Measured by the COMTOL Validated Instrument
Patients who are already taking the medications of interest will be enrolled from a general ophthalmology practice. Immediately after consenting to participate, they will complete a validated survey instrument called the Comparison of Ophthalmic Medication for Primary Outcome Measure Tolerability (COMTOL) questionnaire (Ophthalmology 1997; : 104:334-342). Because this study will not be a crossover trial design, and patients will only continue taking the medications they were prescribed in the course of their glaucoma therapy, the modified version will eliminate questions in the COMTOL related to subjective comparison of two medications and instead focus on tolerability of the single medication being taken by test subjects.
Time frame: at the time of enrollment in the clinic, patients will immediately complete the questionnaire and exit the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.